Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Paratek Pharmaceuticals Inc PRTK

Healthcare Industrials Business Services
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult... see more

Recent & Breaking News (NDAQ:PRTK)

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

GlobeNewswire October 5, 2023

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

GlobeNewswire September 21, 2023

Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

GlobeNewswire September 18, 2023

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

GlobeNewswire September 12, 2023

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

GlobeNewswire September 7, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, NEWR, PRTK

PR Newswire August 28, 2023

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital

PR Newswire August 22, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTK

PR Newswire August 9, 2023

Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

Business Wire August 9, 2023

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

GlobeNewswire August 3, 2023

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings

GlobeNewswire August 2, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRTK, PTEN, NEX, BG

PR Newswire July 18, 2023

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital

PR Newswire July 12, 2023

NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital

PR Newswire July 11, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, PTEN, NEX, PRTK

PR Newswire July 11, 2023

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

GlobeNewswire July 10, 2023

IMPORTANT ALERT: Halper Sadeh LLC Investigates WMC, SGTX, PRTK

PR Newswire June 29, 2023

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

GlobeNewswire June 27, 2023

European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

GlobeNewswire June 27, 2023

NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital

PR Newswire June 27, 2023